EXACT SCIENCES CORPORATION

NASDAQ: EXAS (Exact Sciences Corporation)

最近更新时间: 昨天, 12:30PM

101.06

-0.07 (-0.07%)

前收盘价格 101.13
收盘价格 101.13
成交量 6,091,019
平均成交量 (3个月) 4,967,550
市值 19,177,734,144
预期市盈率 (P/E Forward) 185.19
价格/销量 (P/S) 6.16
股市价格/股市净资产 (P/B) 7.68
52周波幅
38.81 (-61%) — 101.87 (0%)
利润日期 3 Nov 2025
营业毛利率 -36.06%
营业利益率 (TTM) -11.53%
稀释每股收益 (EPS TTM) -5.53
季度收入增长率 (YOY) 10.90%
总债务/股东权益 (D/E MRQ) 105.93%
流动比率 (MRQ) 2.73
营业现金流 (OCF TTM) 323.66 M
杠杆自由现金流 (LFCF TTM) 163.08 M
资产报酬率 (ROA TTM) -1.83%
股东权益报酬率 (ROE TTM) -36.89%

市场趋势

短期 中期
行业 Diagnostics & Research (US) 看涨 混合的
Diagnostics & Research (全球的) 看涨 混合的
股票 Exact Sciences Corporation 看涨 看涨

AIStockmoo 评分

-0.6
分析师共识 -1.5
内部交易活动 NA
价格波动 -5.0
技术平均移动指标 0.0
技术振荡指标 4.0
平均 -0.63

相关股票

股票 市值 DY P/E(TTM) P/B
EXAS 19 B - - 7.68
GH 14 B - - 55.67
RDNT 6 B - - 5.91
VCYT 4 B - 125.55 3.00
NEO 2 B - - 1.86
ATLN 124 M - - 12.93

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It also has a pipeline of blood-based tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

部门 Healthcare
行业 Diagnostics & Research
投资方式 Small Growth
内部持股比例 0.92%
机构持股比例 98.89%
52周波幅
38.81 (-61%) — 101.87 (0%)
目标价格波幅
68.00 (-32%) — 105.00 (3%)
105.00 (Stifel, 3.90%) 保留
105.00 (Canaccord Genuity, 3.90%) 保留
105.00 (Jefferies, 3.90%) 保留
105.00 (Wells Fargo, 3.90%) 保留
105.00 (Barclays, 3.90%) 保留
88.00 (-12.92%)
68.00 (Evercore ISI Group, -32.71%) 购买
平均值 90.08 (-10.87%)
总计 8 购买, 5 保留
平均价格@调整类型 79.57
公司 日期 目标价格 调整类型 价格@调整类型
Stifel 28 Nov 2025 105.00 (3.90%) 保留 101.29
04 Nov 2025 80.00 (-20.84%) 购买 69.59
Canaccord Genuity 25 Nov 2025 105.00 (3.90%) 保留 101.13
Jefferies 24 Nov 2025 105.00 (3.90%) 保留 101.01
Barclays 21 Nov 2025 105.00 (3.90%) 保留 100.90
04 Nov 2025 77.00 (-23.81%) 购买 69.59
Wells Fargo 21 Nov 2025 105.00 (3.90%) 保留 100.90
05 Nov 2025 85.00 (-15.89%) 购买 69.63
Piper Sandler 11 Nov 2025 80.00 (-20.84%) 购买 67.50
08 Oct 2025 70.00 (-30.73%) 购买 59.32
BTIG 04 Nov 2025 85.00 (-15.89%) 购买 69.59
22 Oct 2025 75.00 (-25.79%) 购买 62.91
Baird 04 Nov 2025 88.00 (-12.92%) 购买 69.59
Benchmark 04 Nov 2025 75.00 (-25.79%) 购买 69.59
Guggenheim 04 Nov 2025 75.00 (-25.79%) 购买 69.59
TD Cowen 04 Nov 2025 90.00 (-10.94%) 购买 69.59
Evercore ISI Group 07 Oct 2025 68.00 (-32.71%) 购买 57.75
Craig-Hallum 11 Sep 2025 85.00 (-15.89%) 购买 56.00
显示更多

该时间范围内无数据。

日期 类型 细节
24 Nov 2025 公告 Exact Sciences Reinforces International Leadership in Breast Cancer with Strong Presence at 2025 San Antonio Breast Cancer Symposium
24 Nov 2025 公告 EXAS Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Exact Sciences to Abbott Laboratories
20 Nov 2025 公告 Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments
10 Nov 2025 公告 Exact Sciences Announces Expiration of the HSR Waiting Period for Exclusive License to Freenome’s Blood-Based Colorectal Cancer Screening Tests
07 Nov 2025 公告 Exact Sciences Announces Breakthrough Results from Landmark Study Demonstrating Superior Early Detection of Liver Cancer with Blood-Based Surveillance Test
04 Nov 2025 公告 Exact Sciences to Participate in November Investor Conference
03 Nov 2025 公告 Exact Sciences Announces Third Quarter 2025 Results
27 Oct 2025 公告 Exact Sciences Presents New Findings at ACG 2025 Demonstrating How the Cologuard Test Helps Improve Adherence and Close Screening Gaps
08 Oct 2025 公告 Exact Sciences Schedules Third Quarter 2025 Earnings Call
07 Oct 2025 公告 New Study in Journal of the National Cancer Institute Finds Cologuard Plus™ Provides the Most Life-Years Gained with the Fewest Colonoscopies
22 Sep 2025 公告 Horror Icon Matthew Lillard and Exact Sciences Help Adults 45+ Conquer Fear and Get Screened for Colon Cancer with the Cologuard® Test
10 Sep 2025 公告 Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票